Phase-I open label, dose-escalation clinical trial to evaluate the safety, tolerability and immunogenicity of Chikungunya vaccine in healthy adults of 18 to 50 years age - Chikungunya vaccine
Latest Information Update: 12 Jun 2020
At a glance
- Drugs Chikungunya virus vaccine (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions
- Sponsors Bharat Biotech
- 03 Jun 2020 Results published in the International Vaccine Institute Media Release.
- 30 Apr 2018 Status changed to active, no longer recruiting.
- 30 Jan 2018 Status changed from recruiting to completed.